Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective raised by analysts at Craig Hallum from $30.00 to $35.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Craig Hallum’s target price points to a potential upside of 56.81% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. HC Wainwright boosted their price objective on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Eton Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $39.33.

Eton Pharmaceuticals Stock Up 7.5%

ETON stock opened at $22.32 on Friday. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.63 and a quick ratio of 1.25. The stock has a market capitalization of $598.62 million, a P/E ratio of -123.99 and a beta of 1.19. Eton Pharmaceuticals has a fifty-two week low of $11.09 and a fifty-two week high of $23.00. The business has a 50-day moving average of $16.72 and a 200-day moving average of $17.38.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, March 19th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). The firm had revenue of $21.28 million during the quarter, compared to analyst estimates of $20.58 million. Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.66%. On average, sell-side analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Opaleye Management Inc. increased its position in shares of Eton Pharmaceuticals by 0.3% during the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after purchasing an additional 7,930 shares during the last quarter. EcoR1 Capital LLC boosted its holdings in shares of Eton Pharmaceuticals by 2.0% in the 2nd quarter. EcoR1 Capital LLC now owns 2,030,544 shares of the company’s stock valued at $28,935,000 after buying an additional 40,756 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Eton Pharmaceuticals by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock valued at $29,208,000 after buying an additional 31,942 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Eton Pharmaceuticals by 98.8% in the second quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock valued at $8,450,000 after buying an additional 294,617 shares in the last quarter. Finally, State Street Corp increased its holdings in Eton Pharmaceuticals by 14.5% during the fourth quarter. State Street Corp now owns 501,925 shares of the company’s stock worth $8,488,000 after buying an additional 63,480 shares during the last quarter. 27.86% of the stock is currently owned by institutional investors.

Key Stories Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.